Navigation Links
VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
Date:5/23/2011

SYDNEY, May 23, 2011 /PRNewswire/ -- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel(R) for the treatment of bacterial vaginosis (BV).

Key Points:

  • VivaGel(R) meets primary endpoint, demonstrating significant efficacy for treatment of BV
  • VivaGel(R) expected to avoid many shortcomings of existing therapies
  • Trial results support new patent filing which extends VivaGel(R) protection to at least 2032
  • Planning underway for Phase 3 trials for VivaGel(R) for BV treatment
  • BV prevention trial of VivaGel(R) to commence Q3 2011
  • Addressable global market for BV treatment and prevention potentially exceeds $1B

VivaGel(R) meets primary endpoint, demonstrating significant efficacy for treatment of BV

The study showed that treatment with VivaGel(R) (containing 1% of the active, SPL7013), once daily for seven days, resulted in 74% of patients achieving Clinical Cure of BV 2 to 5 days after completion of therapy compared with just 22% in the placebo group (P=0.0002).

Moreover, 2 to 3 weeks after completion of therapy, 46% of patients achieved Clinical Cure of BV compared with just 12% for the placebo (P=0.006) indicating that VivaGel(R) provided lasting cure in a significant proportion of the women. Both results were highly statistically significant and cure at both time points is considered by clinicians to be important in the clinical management of BV.

The main symptoms of BV are unpleasant vaginal discharge and odour. In Starpharma's study, vaginal BV discharge as assessed by the investigator was cured following treatment in 89% of the VivaGel(R) treated patients. Unpleasant vaginal odour was cured in 78% of the VivaGel(R) treated patients.

Dr Jackie Fairley, Chief Executive Officer of Starpharma, said: "Starpharma's objective is to d
'/>"/>

SOURCE Starpharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... MedImmune today announced,that it has initiated a Phase 1/2a ... children one month to 12 months of age to,help ... most common respiratory infection in infants and can cause ... a serious respiratory disease that can have significant effects,on ...
... Partner to Make Direct Investment in CEL-SCI, ... CVM ) announced today that it has expanded ... Co., Ltd. ("Orient,Europharma"), a leading pharmaceutical company from ... also cover South Korea,the Philippines, Australia and New ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3
(Date:7/31/2015)... ... 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company ... , BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to ... a cure. MaxLife will grant 100% of the money raised to BioViva to help ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a patient's ... heart rate of 150 beats versus 100 beats, this is a big deal," says ... give life back to patients with heart disease," he adds. People with angina are ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... , ... According to WFLA on July 16th, Sarasota has seen ... overdoses. Thricefold deaths have held steady over the last “couple of months” according to ... which was spurred by the crackdown of prescription painkillers. Many users who were addicted ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... reason to deny insurers access to genetic information, argues a ... BMJ. ,Only if we refuse to give ... them seeking genetic test results, says Professor Soren Holm from ... to any health information they would only be able to ...
... of herbal products and medicines has the potential to reach ... the creation of exclusive export promotion zones (EPZ) across ... can be accelerated with the setting up of EPZs in ... rate of over 25 percent in countries like the US, ...
... less than three dollars a year per patient could ... from the trauma and torment of epilepsy, a new ... 85 percent of epilepsy sufferers in the developing world ... the drugs most often prescribed to impede the terrible ...
... find the perfect present this Father's Day? What better way to ... keep him healthy and vital for years to come . This ... check themselves out -- and then get checked out by their ... and over have diabetes. The symptoms of type 2 diabetes, the ...
... getting rid of smoking was more difficult for him than ... ,The former hellraiser, who quit his nicotine addiction in ... hooked to smoking again.,He revealed that before he had kicked ... ,"They're all a b**ger to kick, but I'd ...
... with Prof Vijay K Varadan, an Indian born US ... production of ``glucose watches''. The talks are in the ... ,Varadan holds the post of Director of the Centers ... Density Electronics Center (HiDEC) and Neurosurgery Research Programme in University ...
Cached Medicine News:Health News:Should Genetic Information Be Disclosed to Insurers? 2Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:Small Change Could Stop Epilepsy Seizures for Millions 2Health News:Drag Dad to the Doctor This Father's Day 2Health News:Titan may Produce Glucose Watches Soon 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... The reliable, rugged and easy-to-use solution that's ... is required., ,Symeon's light weight and ... moved into any working position. It can ... And excessive cable "spaghetti syndrome" is minimized ...
... Narkomed 6400 Series anesthesia workstation provides ... technologies are combined to provide true ... user. State of the art computer ... onto a single color touchscreen display ...
... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
Medicine Products: